# A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

> **NCT02025556** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 297 (actual)

## Conditions studied

- Episodic Migraine Headache

## Interventions

- **DRUG:** LBR-101 High Dose
- **DRUG:** LBR-101 Low Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02025556
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-31
- **Primary completion:** 2015-01-31
- **Final completion:** 2015-03-31
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2022-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02025556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02025556, "A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02025556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*